File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation

TitleEffect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation
Authors
Issue Date2013
Citation
Journal of Clinical Oncology, 2013, v. 31, n. 30, p. 3782-3790 How to Cite?
Abstract© 2013 by American Society of Clinical Oncology. Purpose: Killer-cell immunoglobulin-like receptors (KIRs) that regulate natural-killer cells are highly polymorphic. Some KIR2DL1 alleles encode receptors that have stronger signaling function than others. We tested the hypothesis that the clinical outcomes of allogeneic hematopoietic stem-cell transplantation (HSCT) could be affected by donor KIR2DL1 polymorphism. Patients and Methods: All 313 pediatric patients received allogeneic HSCT at a single institution. Donor KIR2DL1 functional allele typing was retrospectively performed using single nucleotide polymorphism assay. Results: Patients who received a donor graft containing the functionally stronger KIR2DL1 allele with arginine at amino acid position 245 (KIR2DL1-R245) had better survival (P = .0004) and lower cumulative incidence of disease progression (P = .001) than those patients who received a donor graft that contained only the functionally weaker KIR2DL1 allele with cysteine at the same position (KIR2DL1-C245). The effect of KIR2DL1 allelic polymorphism was similar in patients with acute myeloid leukemia or acute lymphoblastic leukemia among all allele groups (P ≥ .71). Patients who received a KIR2DL1-R245-positive graft with HLA-C receptor-ligand mismatch had the best survival (P = .00003) and lowest risk of leukemia progression (P = .0005) compared with those who received a KIR2DL1-C245 homozygous graft. Conclusion: Donor KIR2DL1 allelic polymorphism affects recipient outcomes after allogeneic HSCT. These findings have substantial implications for prognostication and donor selection.
Persistent Identifierhttp://hdl.handle.net/10722/294470
ISSN
2020 Impact Factor: 44.544
2015 SCImago Journal Rankings: 9.204
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorBari, Rafijul-
dc.contributor.authorRujkijyanont, Piya-
dc.contributor.authorSullivan, Erin-
dc.contributor.authorKang, Guolian-
dc.contributor.authorTurner, Victoria-
dc.contributor.authorGan, Kwan-
dc.contributor.authorLeung, Wing-
dc.date.accessioned2020-12-03T08:22:48Z-
dc.date.available2020-12-03T08:22:48Z-
dc.date.issued2013-
dc.identifier.citationJournal of Clinical Oncology, 2013, v. 31, n. 30, p. 3782-3790-
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/294470-
dc.description.abstract© 2013 by American Society of Clinical Oncology. Purpose: Killer-cell immunoglobulin-like receptors (KIRs) that regulate natural-killer cells are highly polymorphic. Some KIR2DL1 alleles encode receptors that have stronger signaling function than others. We tested the hypothesis that the clinical outcomes of allogeneic hematopoietic stem-cell transplantation (HSCT) could be affected by donor KIR2DL1 polymorphism. Patients and Methods: All 313 pediatric patients received allogeneic HSCT at a single institution. Donor KIR2DL1 functional allele typing was retrospectively performed using single nucleotide polymorphism assay. Results: Patients who received a donor graft containing the functionally stronger KIR2DL1 allele with arginine at amino acid position 245 (KIR2DL1-R245) had better survival (P = .0004) and lower cumulative incidence of disease progression (P = .001) than those patients who received a donor graft that contained only the functionally weaker KIR2DL1 allele with cysteine at the same position (KIR2DL1-C245). The effect of KIR2DL1 allelic polymorphism was similar in patients with acute myeloid leukemia or acute lymphoblastic leukemia among all allele groups (P ≥ .71). Patients who received a KIR2DL1-R245-positive graft with HLA-C receptor-ligand mismatch had the best survival (P = .00003) and lowest risk of leukemia progression (P = .0005) compared with those who received a KIR2DL1-C245 homozygous graft. Conclusion: Donor KIR2DL1 allelic polymorphism affects recipient outcomes after allogeneic HSCT. These findings have substantial implications for prognostication and donor selection.-
dc.languageeng-
dc.relation.ispartofJournal of Clinical Oncology-
dc.titleEffect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1200/JCO.2012.47.4007-
dc.identifier.pmid24043749-
dc.identifier.pmcidPMC3795888-
dc.identifier.scopuseid_2-s2.0-84891554529-
dc.identifier.volume31-
dc.identifier.issue30-
dc.identifier.spage3782-
dc.identifier.epage3790-
dc.identifier.eissn1527-7755-
dc.identifier.isiWOS:000330540400015-
dc.identifier.issnl0732-183X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats